Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells <i>in vitro</i>

<h4>Background</h4>Chimeric antigen receptor T cell therapy has limited efficacy in the treatment of glioma due to the blood-brain barrier and T cell exhaustion. Enhancement with rabies virus glycoprotein (RVG29) has shown improved brain-related efficacy.<h4>Methods</h4>In this study, we developed CD70R CAR-T cells by modifying anti-CD70 CAR-T cells with RVG29 and tested their tumor-killing ability <i>in vitro</i>.<h4>Results</h4>Transcriptomic profiling via RNA-seq revealed the activated signaling pathways in modified CD70R CAR-T cells. These cells displayed effective <i>in vitro</i> cytotoxicity against CD70⁺; glioma cells, furthermore, co-culture with glioma cells promoted the expansion of quiescent CD70R CAR-T cells.<h4>Conclusion</h4>The RVG29 modification enhances CAR-T therapy for brain tumors and holds promise for treating glioma.